Efficacy of anti-PD-1/PD-L1 antibodies after discontinuation due to adverse events in non-small cell lung cancer patients (HANSHIN 0316)

Efficacy of anti-PD-1/PD-L1 antibodies after discontinuation due to adverse events in non-small cell lung cancer patients (HANSHIN 0316)

Abstract Background Immune checkpoint inhibitors (ICIs) have emerged as promising therapeutic agents in non-small cell lung cancer (NSCLC). However, the duration for which ICIs should be continued remains a clinical problem. Methods We examined the efficacy of anti-PD-1/PD-L1 inhibitors after the di...

Full description

Bibliographic Details
Main Authors: Motoko Tachihara, Shunichi Negoro, Takako Inoue, Motohiro Tamiya, Yuki Akazawa, Takeshi Uenami, Yoshiko Urata, Yoshihiro Hattori, Akito Hata, Nobuyuki Katakami, Soichiro Yokota
Format: Article
Language:English
Published: BMC 2018-10-01
Series:BMC Cancer
Subjects:
Anti-PD-1/L1 inhibitor
Non-small cell lung cancer
Adverse event
Discontinuation
Online Access:http://link.springer.com/article/10.1186/s12885-018-4819-2

Internet

http://link.springer.com/article/10.1186/s12885-018-4819-2

Similar Items